.avif)
WT1 Gene Test - Childhood Cancer Biomarker
A WT1 gene test looks for inherited or new mutations in the WT1 gene that raise risk for Wilms tumor, childhood kidney disease (nephrotic syndrome) and certain disorders of sex development. Knowing your WT1 status enables targeted surveillance, earlier treatment and informed family-planning to reduce cancer and kidney-related complications.
ALK Gene Test - Childhood Cancer Biomarker
This ALK gene test detects mutations or rearrangements in the ALK gene that are linked to cancers—most notably non‑small cell lung cancer, anaplastic large‑cell lymphoma and neuroblastoma. Knowing your ALK status enables earlier detection and access to targeted therapies, improving treatment options and reducing the risk of advanced disease.
WT1 Gene Test - Childhood Cancer Biomarker
This WT1 gene test detects inherited changes in the WT1 gene that raise risk for Wilms tumor and related kidney and gonadal disorders (for example, Denys–Drash and Frasier syndromes). Knowing your WT1 status enables targeted surveillance and early interventions to detect problems sooner and reduce the chance of severe complications.
ALK Gene Test - Childhood Cancer Biomarker
This ALK gene test detects ALK rearrangements and mutations to identify cancers (for example certain non‑small cell lung cancers, anaplastic large‑cell lymphomas and neuroblastomas) that may respond to ALK‑targeted therapies. Knowing your ALK status helps guide more effective, potentially less toxic treatment choices and avoid therapies unlikely to work.
MYCN Amplification Test - Childhood Cancer Biomarker
This MYCN amplification test detects whether a tumor carries extra copies of the MYCN oncogene, a critical prognostic marker used to identify high‑risk neuroblastoma and guide treatment intensity. Knowing MYCN status helps clinicians choose appropriate, timely therapy to reduce the risk of disease progression, relapse, and poor outcomes.
WT1 Gene Test - Childhood Cancer Biomarker
This WT1 gene test detects inherited or de novo mutations that increase risk of Wilms tumor and other WT1‑related kidney and gonadal disorders (e.g., Denys‑Drash, Frasier syndromes). Knowing your result enables targeted surveillance, earlier treatment, and informed family planning to reduce disease-related complications.
MYCN Amplification Test - Childhood Cancer Biomarker
The MYCN amplification test detects whether the MYCN oncogene is amplified in tumor tissue—a key marker used to identify high‑risk neuroblastoma. Knowing MYCN status helps clinicians choose timely, more aggressive treatment and closer monitoring to reduce the risk of disease progression and improve outcomes.
.svg)
